Core Viewpoint - After completing internal control rectification, ST Bailin is set to "remove the hat" and resume trading on June 30, 2024, with its stock name changing from "ST Bailin" to "Guizhou Bailin" [3][5]. Group 1: Company Announcement and Stock Changes - ST Bailin announced that its stock will be suspended for one day on June 27, 2024, and will resume trading on June 30, 2024, with the removal of other risk warnings [3]. - The stock trading limit will change from 5% to 10% following the name change [3]. Group 2: Internal Control Issues and Rectification - In 2023, Guizhou Bailin received a negative opinion in its internal control audit report, leading to the implementation of other risk warnings starting May 6, 2024 [5]. - The company identified significant internal control deficiencies related to sales expense reporting, which affected the accuracy and completeness of financial disclosures [5][6]. - To address these issues, Guizhou Bailin has initiated a comprehensive internal control rectification plan, including the establishment of a compliance management department and the revision of sales expense policies [6]. Group 3: Financial Performance - In 2024, Guizhou Bailin reported a revenue of 3.825 billion yuan, with a net profit attributable to shareholders of 33.62 million yuan, marking a turnaround from previous losses [7][8]. - However, the company's net profit after deducting non-recurring gains and losses was still a loss of 82.44 million yuan, indicating ongoing challenges in core business profitability [7][8]. - The company's stock price has increased by over 20% since the announcement of its "hat removal" application, with a closing price of 5.2 yuan per share as of June 26, 2024, resulting in a total market capitalization of 7.268 billion yuan [9].

Core Viewpoint - Guizhou Bailing Pharmaceutical Group Co., Ltd. (ST Bailing) has applied to revoke its other risk warning status after completing internal control rectifications and ensuring effective operation of its internal controls, meeting the requirements for revocation [1][3] Group 1: Company Actions and Financial Performance - The company has implemented a series of internal control and compliance measures to address previous deficiencies, including the establishment of a compliance management department and hiring third-party consultants for technical support [2][3] - In 2024, ST Bailing achieved operating revenue of 3.825 billion yuan, a decrease of 10.26% compared to 4.263 billion yuan in 2023, while the net profit attributable to shareholders was 33.62 million yuan, marking a significant turnaround from a loss of 415 million yuan in 2023 [4][5] - Despite improvements, the company's non-recurring net profit remained negative at -82.44 million yuan, although this represented an 81.33% reduction in losses compared to the previous year [5] Group 2: Regulatory Background and Compliance Issues - The company was placed under other risk warning status in May 2024 due to a non-standard audit opinion from Tianjian Accounting Firm, which identified significant internal control deficiencies related to sales expense recognition [4] - Prior regulatory inspections revealed multiple issues, including delayed accounting for sales expenses and inaccuracies in financial reporting for 2021 and 2022, leading to administrative measures from the Guizhou Securities Regulatory Bureau [4]